Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03197714
Other study ID # FDO-LMA-2016-01
Secondary ID 2016-004135-21
Status Completed
Phase Phase 1
First received
Last updated
Start date September 7, 2017
Est. completion date March 31, 2020

Study information

Verified date February 2021
Source Hospital Universitario 12 de Octubre
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Phase Ib, open-label, dose-escalation clinical trial to evaluate the best-tolerated doses in Acute Myeloid Leukaemia (AML) relapsed or refractory to chemotherapy. This open-label, nonrandomized trial will comprise 2 stages. A dose escalation stage will characterize the safety, tolerability and maximum tolerated dose (MTD), of OPB-111077. Subsequently, an expansion stage will further evaluate the safety and antitumor activity of OPB-111077 in AML relapsed or refractory to chemotherapy. Enrollment to the expansion cohort will begin following determination of the MTD. Approximately 6-12 patients will be included in the phase I part of this clinical trial. Additional patients will be included in the expansion cohort up to a total of 15 patients. The expansion cohort will serve to further evaluate safety simultaneously with preliminary efficacy. Patients will be selected and included in the study after testing the response to the drug with the Vivia Biotech ex vivo CDx PharmaFlow PM test. PharmaFlow PM test is a companion diagnostic (CDx) tool that provides a complete pharmacological profile for each individual, allowing the detection of patients resistant to OPB-111077 and enriching the study in patients that respond to the drug. The third of patients more sensitive to OPB-11077 wil be included in the study.


Description:

The optimal management of relapsed AML in patients who are not candidates for HSCT has yet to be delineated. Given the median age at which AML is diagnosed and the high incidence of relapse and significant toxicities associated with standard intensive remission induction chemotherapy, new treatment options are needed to optimize AML outcomes. Changes on metabolism are critical in Acute Myeloid Leukaemia (AML); besides, leukemic cells have high requirements of energy and high basal metabolism. For this reason we hypothesized that deregulations of energy metabolism and mitochondria could play a central role in AML. OPB-111077, a novel low-molecular-weight compound discovered by Otsuka Pharmaceutical Co, Ltd, is a new class drug targeting cancer cell metabolisms and STAT3 and is being developed as an orally active antitumor agent for the treatment of various cancers. Sufficient preclinical studies have shown its activity in several types of tumors and especially in AML. Although in a phase I study their activity has been small in a group solid tumor, we may hypostatize that this drug could be more efficient in tumor cells with a high proliferative index as AML. This is an open-label, phase Ib dose-escalation clinical trial to evaluate the safety and tolerability of oral OPB-111077 in AML relapsed or refractory to chemotherapy patients. OPB-111077 will be administered orally on a once daily dose schedule. This open-label, nonrandomized trial will comprise 2 stages. A dose escalation stage will characterize the safety, tolerability and MTD, of OPB-111077. Subsequently, an expansion stage will further evaluate the safety and antitumor activity of OPB-111077 in AML relapsed or refractory to chemotherapy. The overall response rate of OPB-11077 in acute myeloid leukemia and its correlation with the ex-vivo PharmaFlow PM test will be also assessed. Enrollment to the expansion cohort will begin following determination of the MTD. OPB-111077 recommended dose for expansion cohort will be defined during the phase I as MTD. Intra patient dose escalation is not allowed at any time of the study. Patients will be included in the study upon signed informed consent and will follow study procedures. Two dose schemas will be employed: - Level 1: 200 mg daily - Level 2: 250 mg daily The starting dose level of oral OPB-111077 will be 200 mg od. A 3 + 3 dose-escalation scheme will be used. A minimum of 3 patients will be initially enrolled per cohort. DLTs will be assessed during the DLT assessment window of 28 days following the first dose of OPB-111077. Patients who withdraw or are withdrawn from the study prior to completing the DLT assessment window for reasons other than a DLT will not be considered evaluable for DLT and will be replaced. DLTs will be assessed during the DLT assessment window of 28 days following the first dose of OPB-111077. Patients who withdraw or are withdrawn from the study prior to completing the DLT assessment window for reasons other than a DLT will not be considered evaluable for DLT and will be replaced.


Recruitment information / eligibility

Status Completed
Enrollment 9
Est. completion date March 31, 2020
Est. primary completion date March 31, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients at least 18 years old. - Patients diagnosed of non M3 acute myeloid leukemia in relapse after intensive chemotherapy. - Patients with a highest sensitivity (higher 70% of the samples analyzed) in the bone marrow analysis of the OPB-111077 ex-vivo sensitivity test. - Eastern Cooperative Oncology Group (ECOG) performance status = 2. - Bilirubin = 2 × Upper Limit of Normal (ULN). For subjects with known Gilbert's disease, bilirubin = 3.0 mg/dL. - Serum creatinine =2 × ULN or creatinine clearance (CrCl) = 40 mL/min. - Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) = 2.5 × ULN. - Left Ventricular Ejection Fraction (LVEF) must be equal to or greater than 50%. - New York Heart Association (NYHA) congestive heart failure (CHF) class II or better. - Recovery from adverse effects of prior therapy at time of enrollment to = Grade 1 (excluding alopecia). - Life expectancy =3 months - Patients, or appropriate designee, must be able to provide informed consent. Exclusion Criteria: - Individuals with a history of other malignancies. - Subject has uncontrolled intercurrent illness that would limit compliance with study requirements. - Patients diagnosed of M3/Acute promyelocytic leukemia (APL). - The subject has received systemic antineoplastic therapy within 14 days of study treatment. - The subject has received any investigational agent within 28 days before the first dose of study treatment. - The subject has not recovered to baseline or CTCAE = Grade 1 from toxicity due to all prior therapies except alopecia and other non-clinically significant Adverse Events (AEs). - The subject has concurrent uncompensated hypothyroidism or thyroid dysfunction within 7 days before the first dose of study treatment. - Gastrointestinal disorders particularly those associated with a high risk of perforation or fistula formation. - Malabsorption syndrome. - Subject is unable to swallow capsules or tablets. - Subject is pregnant or breastfeeding. - Patients with history of allergic reactions attributed to components of OPB- 111077 that are not easily managed - Subject has systemic infection requiring IV antibiotic therapy within 7 days preceding the first dose of study drug, or other severe infection. - Uncontrolled intercurrent illness that would limit compliance with study requirements. - Patients with serious medical or psychiatric illness likely to interfere with participation in this clinical study.

Study Design


Intervention

Drug:
OPB-111077
Two dose schemas will be employed: Level 1: 200 mg daily Level 2: 250 mg daily

Locations

Country Name City State
Spain Hospital San Pedro Alcántara Cáceres Extremadura
Spain Hospital 12 Octubre Madrid
Spain Hospital Universitario Madrid Sanchinarro Madrid
Spain MD Anderson Cancer Center Madrid
Spain Hospital Virgen del Rocío Sevilla
Spain Hospital Universitario La Fe Valencia

Sponsors (4)

Lead Sponsor Collaborator
Hospital Universitario 12 de Octubre Apices Soluciones S.L., Otsuka Pharmaceutical Co., Ltd., Vivia Biotech

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Dose-limiting toxicity (DLT) of OPB-111077 in patients with in acute myeloid Leukemia. Any adverse event related to the study drug that occurred during the first cycle and considered relevant:
Any Grade 3 or 4 non-hematologic toxicity
Any unexpected non-tolerable grade II adverse event possibly related to the treatment regimen that requires delay beyond 1 week until recovery
Hematological toxicity is not considered doses limiting due to the characteristic of Acute Myeloid Leukemia.
28 days
Secondary Overall response rate. Percentage of patients to reach complete remission (CR), morphologic complete remission with incomplete blood count recovery (Cri) or partial remission (PR) according to Cheson et al criteria. Up to 8 months
Secondary Overall response rate according to IC50 Percentage of patients to reach overall response rate according to IC50. Up to 8 months
Secondary Overall response rate according to Area under de Curve Percentage of patients to reach overall response rate according to area under the curve. Up to 8 months
Secondary Incidence of Treatment-Emergent Adverse Events Number of events per patient according to NCI CTCAE vs 4.03 Up to 8 months
Secondary Progression Free Survival Time from the date of informed consent form to the date of progression or death (from any cause), whichever occurs first Up to 8 months
Secondary Overall Survival Time from the date of informed consent form to the date of death due to any cause Up to 12 months
See also
  Status Clinical Trial Phase
Suspended NCT05400122 - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Phase 1
Recruiting NCT04460235 - Immunogenicity of an Anti-pneumococcal Combined Vaccination in Acute Leukemia or Lymphoma Phase 4
Active, not recruiting NCT03678493 - A Study of FMT in Patients With AML Allo HSCT in Recipients Phase 2
Completed NCT04022785 - PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Phase 1
Recruiting NCT05424562 - A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Canada
Terminated NCT03224819 - Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML) Early Phase 1
Active, not recruiting NCT04070768 - Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113 Phase 1
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Active, not recruiting NCT04107727 - Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML) Phase 2
Recruiting NCT04385290 - Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC) Phase 1/Phase 2
Recruiting NCT04920500 - Bioequivalence of Daunorubicin Cytarabine Liposomes in Naive AML Patients N/A
Recruiting NCT03897127 - Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics Phase 3
Active, not recruiting NCT04021368 - RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Phase 1
Recruiting NCT03665480 - The Effect of G-CSF on MRD After Induction Therapy in Newly Diagnosed AML Phase 2/Phase 3
Completed NCT02485535 - Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant Phase 1
Not yet recruiting NCT06073769 - A Post-Marketing Surveillance Study to Assess the Safety of Oral Azacitidine Maintenance Therapy in Korean Patients With Acute Myeloid Leukemia
Enrolling by invitation NCT04093570 - A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose), With a Food Effect Substudy at Select Study Centers Phase 2
Recruiting NCT04069208 - IA14 Induction in Young Acute Myeloid Leukemia Phase 2
Active, not recruiting NCT05744739 - Tomivosertib in Relapsed or Refractory Acute Myeloid Leukemia (AML) Phase 1
Recruiting NCT04969601 - Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings Phase 1/Phase 2